NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free TMDX Stock Alerts $127.22 -0.06 (-0.05%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$123.62▼$127.9850-Day Range$70.86▼$132.6552-Week Range$36.42▼$132.96Volume637,458 shsAverage Volume769,221 shsMarket Capitalization$4.19 billionP/E RatioN/ADividend YieldN/APrice Target$119.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get TransMedics Group alerts: Email Address TransMedics Group MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside6.5% Downside$119.00 Price TargetShort InterestBearish19.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 39 Articles This WeekInsider TradingSelling Shares$31.62 M Sold Last QuarterProj. Earnings Growth56.45%From $0.62 to $0.97 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.98 out of 5 starsMedical Sector563rd out of 905 stocksElectromedical Equipment Industry10th out of 19 stocks 2.4 Analyst's Opinion Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTransMedics Group has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TransMedics Group's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.22% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in TransMedics Group has recently increased by 5.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMDX. Previous Next 3.1 News and Social Media Coverage News SentimentTransMedics Group has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 39 news articles for TransMedics Group this week, compared to 5 articles on an average week.Search Interest22 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,623,584.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for TransMedics Group are expected to grow by 56.45% in the coming year, from $0.62 to $0.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is -374.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is -374.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 30.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TransMedics Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About TransMedics Group Stock (NASDAQ:TMDX)TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Read More TMDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMDX Stock News HeadlinesMay 8, 2024 | insidertrades.comTransMedics Group, Inc. (NASDAQ:TMDX) Director James R. Tobin Sells 12,025 SharesMay 4, 2024 | insidertrades.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells 15,040 Shares of StockMay 9, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 4, 2024 | insidertrades.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 56,000 Shares of StockApril 19, 2024 | insidertrades.comTransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 SharesApril 14, 2024 | insidertrades.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 12,000 Shares of StockApril 11, 2024 | insidertrades.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 15,512 Shares of StockMay 9, 2024 | finance.yahoo.comInsider Sale: Director Edward Basile Sells Shares of TransMedics Group Inc (TMDX)May 9, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 6, 2024 | seekingalpha.comTransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)May 5, 2024 | finance.yahoo.comTransMedics Group, Inc. (NASDAQ:TMDX) Q1 2024 Earnings Call TranscriptMay 5, 2024 | americanbankingnews.comTamer I. Khayal Sells 63,260 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockMay 5, 2024 | americanbankingnews.comWaleed H. Hassanein Sells 56,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockMay 5, 2024 | americanbankingnews.comJames R. Tobin Sells 15,040 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockMay 4, 2024 | americanbankingnews.comJPMorgan Chase & Co. Raises TransMedics Group (NASDAQ:TMDX) Price Target to $127.00May 4, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Earns Overweight Rating from Piper SandlerMay 4, 2024 | americanbankingnews.comTransMedics Group, Inc. to Post Q2 2024 Earnings of $0.10 Per Share, William Blair Forecasts (NASDAQ:TMDX)May 3, 2024 | finance.yahoo.comTransMedics Group First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | finance.yahoo.comShould You Think About Buying TransMedics Group, Inc. (NASDAQ:TMDX) Now?May 3, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) PT Raised to $125.00May 3, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) PT Raised to $117.00 at Canaccord Genuity GroupMay 3, 2024 | americanbankingnews.comWilliam Blair Weighs in on TransMedics Group, Inc.'s Q3 2025 Earnings (NASDAQ:TMDX)May 2, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Price Target Raised to $130.00 at TD CowenMay 2, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Sets New 1-Year High on Better-Than-Expected EarningsMay 1, 2024 | wsj.comTransMedics Group Inc.May 1, 2024 | fool.comWhy TransMedics Stock Is Soaring TodayMay 1, 2024 | msn.comCrude Oil Down 3%; ISM Manufacturing PMI Falls In AprilSee More Headlines Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today5/09/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:TMDX CUSIPN/A CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees584Year FoundedN/APrice Target and Rating Average Stock Price Target$119.00 High Stock Price Target$130.00 Low Stock Price Target$95.00 Potential Upside/Downside-6.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E Ratio205.19 P/E GrowthN/ANet Income$-25,030,000.00 Net Margins-3.43% Pretax Margin-3.92% Return on Equity7.95% Return on Assets1.61% Debt Debt-to-Equity Ratio3.18 Current Ratio9.72 Quick Ratio8.76 Sales & Book Value Annual Sales$241.62 million Price / Sales17.34 Cash Flow$0.14 per share Price / Cash Flow899.20 Book Value$4.20 per share Price / Book30.29Miscellaneous Outstanding Shares32,940,000Free Float30,631,000Market Cap$4.19 billion OptionableOptionable Beta1.87 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Waleed H. Hassanein M.D. (Age 56)Founder, President, CEO & Director Comp: $1.82MMr. Stephen Gordon (Age 56)CFO, Treasurer & Secretary Comp: $909.62kMr. Mark AndersonSenior Director of Technology DevelopmentKey CompetitorsIntegerNYSE:ITGRLivaNovaNASDAQ:LIVNCONMEDNYSE:CNMDSoleno TherapeuticsNASDAQ:SLNOInModeNASDAQ:INMDView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Bought 26,997 shares on 5/8/2024Ownership: 0.082%ProShare Advisors LLCBought 427 shares on 5/8/2024Ownership: 0.018%Entropy Technologies LPBought 2,715 shares on 5/8/2024Ownership: 0.008%Headlands Technologies LLCSold 1,846 shares on 5/8/2024Ownership: 0.001%SG Americas Securities LLCSold 433 shares on 5/7/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions TMDX Stock Analysis - Frequently Asked Questions Should I buy or sell TransMedics Group stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMDX shares. View TMDX analyst ratings or view top-rated stocks. What is TransMedics Group's stock price target for 2024? 8 brokers have issued 12 month target prices for TransMedics Group's stock. Their TMDX share price targets range from $95.00 to $130.00. On average, they predict the company's stock price to reach $119.00 in the next twelve months. This suggests that the stock has a possible downside of 6.5%. View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts. How have TMDX shares performed in 2024? TransMedics Group's stock was trading at $78.93 at the start of the year. Since then, TMDX stock has increased by 61.2% and is now trading at $127.22. View the best growth stocks for 2024 here. When is TransMedics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our TMDX earnings forecast. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) issued its quarterly earnings data on Tuesday, April, 30th. The company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.40. The company earned $96.90 million during the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive trailing twelve-month return on equity of 7.95% and a negative net margin of 3.43%. The business's revenue was up 132.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.08) earnings per share. What ETFs hold TransMedics Group's stock? ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Clough Select Equity ETF (CBSE), Clough Long/Short Equity ETF (CBLS), Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), BNY Mellon Innovators ETF (BKIV), Principal Healthcare Innovators ETF (BTEC) and First Trust Multi-Manager Small Cap Opportunities ETF (MMSC). What guidance has TransMedics Group issued on next quarter's earnings? TransMedics Group updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $390.0 million-$400.0 million, compared to the consensus revenue estimate of $367.0 million. What is Waleed Hassanein's approval rating as TransMedics Group's CEO? 17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS). When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? TransMedics Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (2.23%), Allspring Global Investments Holdings LLC (2.23%), Wasatch Advisors LP (1.33%), Baillie Gifford & Co. (0.93%), Sei Investments Co. (0.34%) and Peregrine Capital Management LLC (0.23%). Insiders that own company stock include David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, Laura Damme, Miriam Provost, Nicholas Corcoran, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TMDX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
